**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2016-17/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS 150 mg/200 mg/300 mg | | REF. NO: NDQD201508113 |
| **DATE RECEIVED:** 06.08.2015 | **LABEL CLAIM:** | Each film coated tablet contains: Lamivudine USP 150 mg, Nevirapine USP 200 mg and Zidovudine USP 300 mg. | |
| **BATCH NO.:** 3024309 | **PRESENTATION:** | Sky blue coloured, film-coated caplets embossed 'M104' on one face but plain on the other, packed in a white, plastic, multi-dose container carrying 60 tablets in a unit box. | |
| **MGF. DATE:** Mar. 2014 | **MANUFACTURER:** | MYLAN Laboratories Ltd. | |
| **EXP. DATE:** Mar. 2019 | **ADDRESS:** | H-12 & H-13, MIDC, Waluj, Aurangabad - 431136, Maharashtra, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | National AIDS and STI Control Programme P.O. BOX 19361 Nairobi | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2012 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In-House Method | RT of the component peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 2.9, 3.8 and 5.2 +/- 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Lamivudine 98.0% (RSD = 1.2%; n = 6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Nevirapine 93.8% (RSD = 0.6%; n = 6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Zidovudine 98.1% (RSD = 2.5%; n = 6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Lamivudine 99.7% (RSD = 0.6%; n = 9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Nevirapine 96.3% (RSD = 0.2%; n = 9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | Zidovudine 99.7% (RSD = 0.5%; n = 9) | **COMPLIES:COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. E. MUTUA |  | DATE:30-09-2015 |
| REVIEWER: | DR. G. WANG'ANG'A |  | DATE:12-10-2015 |
| ANALYST: | SERAH MUTERU |  | DATE:10-21-2015 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:01-14-2016 |